Sali M, Delogu G, Greco E, Rocca S, Colizzi V, Fadda G, Fraziano M
Institute of Microbiology, Catholic University of the Sacred Heart, Rome, Italy.
Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):175-81. doi: 10.1177/039463200902200120.
Sphingosine 1-phosphate (S1P) is a natural lysophospholipid able to enhance antimycobacterial innate immune response. In the present study, we address the possible therapeutic role of S1P administered during primary or acute infection in mice aerogenically infected with Mycobacterium tuberculosis (MTB). Results show that the administration of S1P during primary infection significantly reduces the presence of MTB-infected cells within pulmonary granulomas and mycobacterial burden in the lung and in the spleen. However, if S1P treatment was started during acute infection, a detrimental effect was observed in terms of pulmonary histopathology and mycobacterial burden in the lung and in the spleen. Taken together, these results show that S1P can exert a therapeutic effect as a treatment of primary infection only.
鞘氨醇-1-磷酸（S1P）是一种天然溶血磷脂，能够增强抗分枝杆菌的固有免疫反应。在本研究中，我们探讨了在经空气感染结核分枝杆菌（MTB）的小鼠原发性或急性感染期间给予S1P可能的治疗作用。结果表明，在原发性感染期间给予S1P可显著减少肺肉芽肿内MTB感染细胞的数量以及肺和脾脏中的分枝杆菌负荷。然而，如果在急性感染期间开始S1P治疗，则在肺组织病理学以及肺和脾脏中的分枝杆菌负荷方面会观察到有害作用。综上所述，这些结果表明S1P仅作为原发性感染的治疗方法可发挥治疗作用。
